PET Imaging for Abdominal Aortic Aneurysm

(PET AAA Trial)

This trial tests a new imaging method, Cu-64-RYM2 (a radioactive imaging agent), with PET/CT to assess its safety and effectiveness in detailing abdominal aortic aneurysms (AAA) before surgery. The researchers aim to understand how the body processes this imaging agent and how it compares to actual tissue samples. Healthy volunteers without major health issues and individuals with AAA needing surgery may be suitable for this study. Participants must be comfortable lying still in a scanner for about an hour. As an Early Phase 1 trial, this research focuses on understanding how this new imaging method works in people, offering participants a chance to contribute to groundbreaking medical advancements.

The trial information does not specify if you need to stop taking your current medications. However, it mentions that patients with AAA should have medically managed hypertension and hyperlipidemia, suggesting that continuing these medications might be necessary.

In previous studies, the treatment under testing, called Cu-64-RYM2, did not cause harmful effects in mice, indicating safety for the animals. When combined with a special form of copper, Cu-64, used in imaging tests, the treatment remained stable in both mouse and human blood. Stability is crucial because it ensures the treatment functions properly without breaking down in the body.

Unlike traditional treatments for abdominal aortic aneurysms, which typically involve surgical intervention, Cu-64-RYM2 offers a novel approach by utilizing PET imaging. This method uses a radioactive tracer that targets specific proteins in the aneurysm, allowing for detailed imaging and potentially earlier detection of changes in the aneurysm's size or activity. Researchers are excited about this treatment because it could provide a non-invasive way to monitor aneurysms, leading to more timely and personalized treatment plans.

Research has shown that Cu-64-RYM2 holds promise for imaging abdominal aortic aneurysms (AAA). Studies indicate it effectively attaches to both normal and swollen aortic tissues, which are linked to tissue breakdown in aneurysms. This tracer provides clear PET images, aiding doctors in visualizing these areas. The trial will evaluate Cu-64-RYM2 in patients with AAA and healthy volunteers to monitor and assess the condition more effectively. Early data suggest that Cu-64-RYM2 offers good imaging contrast, simplifying the identification of problem areas in the aorta.²⁴⁶⁷⁸